why did the fda ban bpc 157 Banned: Key Facts on Latest Decision NBC News | The claims

Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study

Indeed, in our first on-treatment analysis at week 208, weight loss was greater (11.7% for semaglutide) compared with the in-trial analysis (10.2% for semaglutide)

Mechanistically, TB-500s parent peptide (T4) drives endothelial cell migration, tubule formation, and angiogenesis, processes essential for granulation tissue and perfusion during healing

The recommended schedule from clinical trials is: Weeks 1-4: 2.5 mg once weekly Weeks 5-8: 5 mg once weekly Weeks 9-12: 7.5 mg once weekly Weeks 13-16: 10 mg once weekly Weeks 17-20: 12.5 mg once weekly Week 21+: 15 mg once weekly (maximum dose) Not everyone follows this exact schedule

SLU-PP-332 sits in an unusual position among research compounds: the published pharmacology says one thing about how to deliver it, and most vendors are selling something else